With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...
Zacks Investment Research on MSN
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
Bayer AG BAYRY reported third-quarter 2025 core earnings of 17 cents per American Depositary Receipt (ADR), which comfortably ...
Investing.com -- Bayer AG (ETR:BAYGN) on Wednesday reported a 138% jump in quarterly earnings, lifted by higher margins in ...
Bayer AG (($BAYRY)) announced an update on their ongoing clinical study. Bayer AG, in collaboration with Janssen Research & Development, LLC, has ...
Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of Lynkuet.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback